• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Adare Pharma Solutions

    PCI Pharma Services

    Syngene

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Alcami

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    A New Era of Vaccine and Biologic Drug Development

    As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.

    A New Era of Vaccine and Biologic Drug Development
    Kristin Brooks, Managing Editor01.12.21
    The Biopharmaceutical industry has achieved remarkable success and innovation these past few years, namely the first CAR-T cell therapy and antibody drug conjugate (ADC) approvals. Significantly, the global pandemic has fueled vaccine innovation with the rapid acceleration of RNA based COVID vaccines.
     
    Currently, nine ADCs have received market approval, and in July 2020, the U.S. FDA approved the third CAR-T cell therapy, Tecartus, a cell-based gene therapy for treatment of mantle cell lymphoma (MCL). Additionally, to date, Pfizer-BioNTech’s COVID-19 Vaccine and Moderna’s COVID-19 Vaccine have been approved by the FDA for emergency use.
     
    Along with these advances, there has been a significant increase in outsourcing, particularly related to vaccine manufacture and fill finish, as well as drug research and development, analytical services, and manufacturing.
     
    As the number of advanced therapy medicinal products (ATMPs) in development continue to grow, new production strategies are helping to address the inherent development and manufacturing challenges associated with these therapies.
     
    Alex Perieteanu, Ph.D., Director of Biopharmaceutical Services at SGS Life Sciences discusses the future of vaccines and biologics, how the pandemic is impacting outsourcing and operations, and the challenges and advances in manufacturing cell therapies. –KB
     
    Contract Pharma: With the current COVID climate what do you anticipate for the future of vaccines and biologics?
     
    Alex Perieteanu: As an outcome of COVID-19, we’ve entered a new era of vaccine and biological drug development. The pandemic has demanded unprecedented investment into vaccines, diagnostics, and treatments.  In a relatively short period of time, this has had a tremendous impact on the Biotechnology industry and the momentum is likely to continue.  Looking at vaccines alone, we’ve seen a rapid acceleration in LNP-mRNA based approaches, a promising technology, but one that had yet to mature to commercialization. That is, until recently, two COVID-19 vaccines have recently received FDA emergency use authorization (EUA) to combat COVID-19.
     
    CP: How has the pandemic impacted outsourcing and operations? 
     
    AP: Many organizations have had to carefully evaluate outsourcing strategies, internal capacities, priorities, and risks.  It’s of little surprise that we’ve seen an increase in demand across the board.  Whether it be for high priority activities related to Covid-19, supply chain diversification, or whether it is simply due to a needing to strategically outsource in order to manage internal capacities.   
     
    CP: What capabilities will be needed down the road?
     
    AP: A very difficult question, as almost everything is in demand.  With a tidal wave of COVID-19 related investigational new drug applications (INDs), the ability to support GMP level manufacturing as well as analytical testing, is and will be in high demand. Capabilities and experience in the nucleotide and vector-based delivery space (viral and non-viral) are going to be highly sought after in the near term and will continue until the market adjusts to an increased demand.
     
    CP: Are there specific geographical markets that are key? 
     
    AP: This pandemic has had a global impact. All markets with established capabilities are likely to see rapid growth in the sector; however, with such high demand, regions or nations whom otherwise do not have significant local production capabilities may look to fund, or partially nationalize some basic levels of production in order to ensure long term supply.
     
    CP: In what services areas are you seeing the most growth?
     
    AP: Development, clinical trials, and manufacturing are all integral parts of bringing a molecule to market, and one cannot be done without the other.  We’re seeing proportional growth in all areas. 
     
    CP: With the advances in cell and gene therapies, what type of growth do you anticipate? Is the industry positioned to accommodate future growth?
     
    AP: Cell and gene therapies, or advanced therapy medicinal products (ATMPs) offer groundbreaking new opportunities for the treatment of disease or injury.  While only a relatively small number of ATMPs have received regulatory approval, the number of active INDs in this category is expected to break 1,000 by the end of 2021.  
     
    With a promise to revolutionize medicine, ATMPs are very likely to become a staple in 21st century medicine. The industry has been adapting to the emergence of ATMPs with significant investments in product development, and manufacturing technology. Ultimately, vector delivery systems, complexity of manufacturing, an evolving regulatory landscape, and finally cost remain at the crux these emerging technologies. 
     
    CP: What are the current challenges developing and manufacturing these therapies and where are advances being made?
     
    AP: A major challenge with gene therapies is genetic uptake, and the need for a vector to facilitate this delivery. The field is currently dominated by adeno-associated virus (AAV) delivery systems which are difficult to scale and many have fallen short of their supply demands for Phase II/III trials.  To help resolve this, a number of production strategies have been developed such as the use of Baculovirus and PiggyBacTM expression systems, and Helper-Free Transfection systems. Non-viral based delivery systems such as lipid nanoparticles also show a high potential of resolving many manufacturing issues associated with viral based systems while delivering a highly scalable production solution.
     
    Cell therapies are also challenged by complex manufacturing involving hundreds of distinct and often manual steps during manufacturing. Worse, for autologous therapies this is needed on a patient by patient basis.  Standardization, and automation technologies, such as Lonza’s CocoonTM are likely to drive simplified and standardized workflows.
     
    Overall, ATMPs suffer from complex, and comparatively small scale manufacturing. Which, while not insurmountable, lends to another very real problem; Cost. Cell and gene therapies are among the most costly therapeutics available and dose regiments can reach costs in the hundreds of thousands.  Thus, cost is seen as one of the largest hindrances to commercial adoption.
     
     
    Alex Perieteanu, Ph.D. serves as the Director of Biopharmaceutical Services for SGS Toronto. Alex and his team of more than 85 scientists have successfully supported numerous IND submissions and BLA fillings; supporting CMC and R&D activities ranging from early-phase characterization, shelf-life stability, forced degradation, to analytical support during process validation, performance monitoring, and remediation activities. Dr. Perieteanu and his team have experience working on numerous biologics, and advanced therapy medicinal products and various stages in development and commercialization.  Alex brings expertise in Protein Structure and Function Biochemistry with a Ph.D in Biophysics and a focus on protein engineering. Alex has been with SGS for nearly 10 years, and before joining SGS was with Sanofi Pasteur Analytical R&D, and with the Structural Genomics Consortium.
     
    Related Searches
    • Analytical Services
    • Biologics, Proteins, Vaccines
    • Drug Development

    Related Online Exclusives

    • Analytical Services | Laboratory Testing
      Improving Product Profitability

      Improving Product Profitability

      Using PAT/QbD/CM as tools to increase profitability of products.
      Emil Ciurczak, Contributing Editor 01.21.21

    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Drug Delivery | Drug Development
      Inhaled Drug Delivery Technology Trends

      Inhaled Drug Delivery Technology Trends

      The success of new inhaled medicines relies on the correct combination of formulation and device technology.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 11.24.20


    • Bioanalytical Services | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      CDMOs: Keeping up with Science & Technology

      CDMOs: Keeping up with Science & Technology

      Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.
      Kristin Brooks, Contract Pharma 11.12.20

    • Biologics, Proteins, Vaccines
      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      CMOs expand and ‘repurpose’ capacities.
      S Harachand, Contributing Editor 10.20.20

    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20


    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20

    • Drug Development | Information Technology
      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Theft of IP belonging to companies developing biologics and other drugs, including COVID-19 treatments and vaccines, poses a threat to innovation.
      Kristin Brooks, Contract Pharma 08.19.20

    • Drug Development | Industry News
      Top Companies Report: Biogen

      Top Companies Report: Biogen

      Expands pipeline of disease-modifying therapies for Alzheimer’s and Parkinson’s, adds gene therapies focused on AAV treatments, bolsters biosimilars portfolio.
      Kristin Brooks, Contract Pharma 07.10.20


    • Biologics, Proteins, Vaccines | Drug Discovery
      Cell Therapy for Solid Tumors

      Cell Therapy for Solid Tumors

      Is base editing the solution for solid tumor-based cell therapy?
      Jonathan Frampton, Corporate Development Partner, Horizon Discovery 06.26.20

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20

    • Drug Development | Information Technology
      Advancing AI Initiatives in R&D

      Advancing AI Initiatives in R&D

      Richard Lee of ACD/Labs discusses the possibilities of using AI in R&D, and what this outlook means for IT leaders at pharmaceutical organizations.
      Kristin Brooks, Contract Pharma 06.11.20


    • Clinical Trials | CRO News | Drug Development | Information Technology | R&D
      CRO Industry Update

      CRO Industry Update

      Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
      Kristin Brooks, Contract Pharma 04.27.20

    • Drug Development | R&D
      COVID-19 and the Importance of Combating Antimicrobial Resistance

      COVID-19 and the Importance of Combating Antimicrobial Resistance

      Dr. Frank of Working to Fight AMR discusses the global COVID-19 pandemic and the critical need to address the public health crisis of Antimicrobial Resistance
      Kristin Brooks, Contract Pharma 04.13.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trials | Drug Development | Scale-up/Technology Transfer
      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Contract Pharma 04.03.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Pfizer, BioNTech Enter Vax Pact With COVAX
    • CONTINUUS Awarded $69.3M DoD Grant
    • Nexelis Acquires GSK Vax Lab In Marburg
    • Piramal Inks Clinical Supply Deal With Theratechnologies
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login